Cargando…

First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia

INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunos...

Descripción completa

Detalles Bibliográficos
Autores principales: Peinemann, Frank, Grouven, Ulrich, Kröger, Nicolaus, Bartel, Carmen, Pittler, Max H., Lange, Stefan
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081818/
https://www.ncbi.nlm.nih.gov/pubmed/21541024
http://dx.doi.org/10.1371/journal.pone.0018572
_version_ 1782202239088066560
author Peinemann, Frank
Grouven, Ulrich
Kröger, Nicolaus
Bartel, Carmen
Pittler, Max H.
Lange, Stefan
author_facet Peinemann, Frank
Grouven, Ulrich
Kröger, Nicolaus
Bartel, Carmen
Pittler, Max H.
Lange, Stefan
author_sort Peinemann, Frank
collection PubMed
description INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunosuppressive therapy may be offered as alternative. The aim was to compare the outcome of these patients in controlled trials. METHODS: A systematic search was performed in the bibliographic databases MEDLINE, EMBASE, and The Cochrane Library. To show an overview of various outcomes by treatment group we conducted a meta-analysis on overall survival. We evaluated whether studies reported statistically significant factors for improved survival. RESULTS: 26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. We did not identify any RCTs. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. CONCLUSIONS: Young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies.
format Text
id pubmed-3081818
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-30818182011-05-03 First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia Peinemann, Frank Grouven, Ulrich Kröger, Nicolaus Bartel, Carmen Pittler, Max H. Lange, Stefan PLoS One Research Article INTRODUCTION: Acquired severe aplastic anemia (SAA) is a rare and progressive disease characterized by an immune-mediated functional impairment of hematopoietic stem cells. Transplantation of these cells is a first-line treatment option if HLA-matched related donors are available. First-line immunosuppressive therapy may be offered as alternative. The aim was to compare the outcome of these patients in controlled trials. METHODS: A systematic search was performed in the bibliographic databases MEDLINE, EMBASE, and The Cochrane Library. To show an overview of various outcomes by treatment group we conducted a meta-analysis on overall survival. We evaluated whether studies reported statistically significant factors for improved survival. RESULTS: 26 non-randomized controlled trials (7,955 patients enrolled from 1970 to 2001) were identified. We did not identify any RCTs. Risk of bias was high except in 4 studies. Young age and recent year of treatment were identified as factors for improved survival in the HSCT group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the IST group. In 19 studies (4,855 patients), summary statistics were sufficient to be included in meta-analysis. Considerable heterogeneity did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. CONCLUSIONS: Young age and recent year of treatment were identified as factors for improved survival in the transplant group. Advanced age, SAA without very severe aplastic anemia, and combination of anti-lymphocyte globulin with cyclosporine A were factors for improved survival in the immunosuppressive group. Considerable heterogeneity of non-randomized controlled studies did not justify a pooled estimate. Adverse events were inconsistently reported and varied significantly across studies. Public Library of Science 2011-04-25 /pmc/articles/PMC3081818/ /pubmed/21541024 http://dx.doi.org/10.1371/journal.pone.0018572 Text en Peinemann et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Peinemann, Frank
Grouven, Ulrich
Kröger, Nicolaus
Bartel, Carmen
Pittler, Max H.
Lange, Stefan
First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title_full First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title_fullStr First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title_full_unstemmed First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title_short First-Line Matched Related Donor Hematopoietic Stem Cell Transplantation Compared to Immunosuppressive Therapy in Acquired Severe Aplastic Anemia
title_sort first-line matched related donor hematopoietic stem cell transplantation compared to immunosuppressive therapy in acquired severe aplastic anemia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3081818/
https://www.ncbi.nlm.nih.gov/pubmed/21541024
http://dx.doi.org/10.1371/journal.pone.0018572
work_keys_str_mv AT peinemannfrank firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia
AT grouvenulrich firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia
AT krogernicolaus firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia
AT bartelcarmen firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia
AT pittlermaxh firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia
AT langestefan firstlinematchedrelateddonorhematopoieticstemcelltransplantationcomparedtoimmunosuppressivetherapyinacquiredsevereaplasticanemia